SCHEMBL7513237

SCHEMBL7513237

CN(C)CCn1c(-c2ccc(C=O)cc2)nc2cc(Cl)c(Cl)cc21

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.43
KDM4E B2RXH2 4/20 0.43
LMNA P02545 2/20 0.43
HDAC1 Q13547 1/20 0.42
HDAC8 Q9BY41 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
PTGER4 P35408 4/20 0.41
RHEB Q15382 1/20 0.41
KCNH2 Q12809 1/20 0.40
MAPT P10636 1/20 0.39
CNR2 P34972 2/20 0.38
ALDH1A1 P00352 1/20 0.38
HPGD P15428 1/20 0.38
HTT P42858 1/20 0.38
DCTPP1 Q9H773 2/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
DRD2 P14416 1/20 0.36
DRD3 P35462 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7519324 0.85 KDM4E (0.52) BRD4KDM4ELMNARHEBKCNH2
SCHEMBL7556213 0.82 MGAM (0.55) BRD4HPGDHTT
SCHEMBL7556207 0.82 MGAM (0.55) BRD4HPGDHTT
SCHEMBL7517543 0.80 PRSS12 (0.46) BRD4KDM4ELMNAHDAC1HDAC8
SCHEMBL7517579 0.80 KDM4E (0.59) BRD4KDM4ELMNAPTGER4RHEB
SCHEMBL7514725 0.79 RHEB (0.51) BRD4KDM4ELMNARHEBKCNH2
SCHEMBL7512060 0.79 RHEB (0.56) BRD4LMNARHEBKCNH2MAPT
SCHEMBL7391548 0.78 PTGER4 (0.42) BRD4KDM4ELMNAHDAC1HDAC8
SCHEMBL7520505 0.78 KCNH2 (0.65) BRD4KDM4ELMNARHEBKCNH2
SCHEMBL7516898 0.76 RHEB (0.43) BRD4KDM4ELMNARHEBKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6452014-B1 THIAZOLIDINEDIONE COMPOUNDS GERON CORPORATION 2002-09-17 US disclosed
US-20020120144-A1 Telomerase inhibitors and methods of their use KYOWA HAKKO KOGYO CO., LTD. (JP) 2002-08-29 US disclosed
WO-2002051409-A1 TELOMERASE INHIBITORS AND METHODS OF THEIR USE GERON CORPORATION (US) 2002-07-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020120144-A1 Telomerase inhibitors and methods of their use TERT, TERF2, POT1 BRD4 89/4885KDM4E 1936/4885LMNA 156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.